LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway is a research paper published in International Journal of Molecular Sciences (2022). On theSindex it has a DataRank of 0.457. It has been cited 20 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.457
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →the National Natural Science Foundation of China
Grant: 81902357
the National Natural Science Foundation of China
Grant: cstc2020jcyj-msxmX0004
the National Natural Science Foundation of China
Grant: 2022M710550
the National Natural Science Foundation of China
Grant: 2021yc-jckx20042
FWCI
1.41
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
Additional file 1 of Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs